About this trial
Why Is This Research Study Being Conducted?
* The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS
Eligibility criteria
Qualifiers
Age ≥18 years
Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms
Eastern Cooperative Oncology Group (ECOG) performance status ≤3
Expected survival of at least 6 months
Disqualifiers
Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis
Hematopoietic stem cell transplantation expected within 6 months
Trial design
Treatments tested in this trial
- Observational